Uridine triacetate
As of the edition of 20 October 2026, Uridine triacetate is a small molecule: marketed, first approved in 2015 (US); no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2015
- Kind
- Small molecule
- Brand name
- Xuriden
- First approved
- 4 September 2015 (US)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Btg
- Registered trials
- 4, 1 stopped early
- Disease areas
- Cancer; Digestive system; Nutrition and metabolism
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 1 | 0 | 0 | 1 |
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 3 | 1 | 1 | 0 | 0 |
| All trials | 4 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Wellstat Therapeutics | Originator and Lead sponsor of trials | 2014 to now |
| Btg | Acquired holder | 2023 to now |